RxDoctor Payments Data

Albert Mamary, MD

Pulmonary Disease · Philadelphia, PANPI 1407808033

Payments from drug & device makers

$378in general payments, 2019–2025

Across 10 payments — averaging $37.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$232
  • Harmony Biosciences LLC$76
  • Inspire Medical Systems, Inc.$40
  • Avadel CNS Pharmaceuticals, LLC$29

What the payments were for

  • Food & beverage$30180%
  • Education$7720%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$378 in reported general payments places this provider in the 30th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$206,946
Medicare patients
181
Services billed
5,672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucalaMepolizumab64$575,738
PrevymisLetermovir55$397,463
OpsumitMacitentan24$307,553
OfevNintedanib Esylate16$208,819
WinrevairSotatercept-Csrk11$156,825
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5014$117,118
Trelegy ElliptaFluticasone/Umeclidin/Vilanter95$79,010
Atovaquone94$53,275
Breo ElliptaFluticasone/Vilanterol90$45,064
EliquisApixaban47$35,517
NulojixBelatacept13$26,446
Valganciclovir Hcl78$15,723
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$14,528
Spiriva RespimatTiotropium Bromide15$11,954
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$11,849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$232$307,55324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →